Loading
NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.
Histone methyltransferase that dimethylates Lys-36 of histone H3 (H3K36me2). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context.
Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.68, somatic mutation 0.74, genetic literature 0.83). IntOGen calls it a driver in 15 cohorts (3 activating, 12 loss-of-function), covering Bladder Urothelial Carcinoma, Cervical Adenocarcinoma, Oesophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Melanoma and others.
In plain words · NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.
NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.
Histone methyltransferase that dimethylates Lys-36 of histone H3 (H3K36me2). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context.
No product in this corpus aims at NSD1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 2001. Earliest sequence paper UniProt cites for the protein: Wang et al, J. Biol. Chem, 2001, "Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells". Source.
Sources: HGNC HGNC:14234 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96L73 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000165671 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: head and neck squamous cell carcinoma 0.54, acute myeloid leukaemia 0.66, myeloproliferative neoplasm 0.66, leukaemia 0.67 (GraphQL API, CC0)); IntOGen NSD1 (driver in 15 cohorts (Act 3, LoF 12); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Histone methyltransferase that dimethylates Lys-36 of histone H3 (H3K36me2). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context. Location: Nucleus; Chromosome (UniProt). Locus 5q35.3 (HGNC).
Query for this target: (TITLE:"NSD1" OR ABSTRACT:"NSD1" OR TITLE:"nuclear receptor binding SET domain protein 1" OR ABSTRACT:"nuclear receptor binding SET domain protein 1" OR TITLE:"Histone-lysine N-methyltransferase, H3 lysine-36 specific" OR ABSTRACT:"Histone-lysine N-methyltransferase, H3 lysine-36 specific" OR TITLE:"ARA267" OR ABSTRACT:"ARA267" OR TITLE:"FLJ22263" OR ABSTRACT:"FLJ22263" OR TITLE:"KMT3B" OR ABSTRACT:"KMT3B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NSD1, not a curated reading list.
Shares Leukaemia (all types), Cervical cancer, Bladder & urothelial cancer, IntOGen.
Shares Leukaemia (all types), Endometrial cancer, Oesophageal cancer, Cervical cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Endometrial cancer, IntOGen.
Shares Leukaemia (all types), Endometrial cancer, IntOGen, Head and neck squamous cell carcinoma.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Endometrial cancer, Bladder & urothelial cancer.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), IntOGen, Non-Hodgkin lymphoma (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Bladder & urothelial cancer, IntOGen.
Shares Leukaemia (all types), Bladder & urothelial cancer, IntOGen, Head and neck squamous cell carcinoma.